Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL9999345 | 0.93 | PIK3CD (0.41) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL9986533 | 0.89 | PIK3CD (0.47) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL9986601 | 0.83 | PIK3CD (0.46) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL9986481 | 0.82 | PIK3CD (0.48) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| Trifluoroacetic Acid SCHEMBL9999180 | 0.82 | PIK3CD (0.46) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL9987784 | 0.82 | PIK3CD (0.44) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL9998908 | 0.81 | PIK3CD (0.47) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL12688591 | 0.80 | PIK3CD (0.66) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL9999444 | 0.80 | PIK3CD (0.51) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL357319 | 0.80 | PIK3CD (0.64) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | claimed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | claimed |
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| WO-2011163195-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R4, PIK3CA | PIK3CD 8/4885PIK3R1 4/4885PIK3CA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.